Allurion Technologies announces presentation of four abstracts at ECO

The company states: “Allurion Technologies (ALUR) announced the presentation of four abstracts at the European Congress on Obesity – ECO – taking place in Malaga, Spain, May 11-14, 2025. These studies highlight the transformative impact of the Allurion Balloon and the Virtual Care Suite – the AI-powered digital platform that includes Coach Iris-on weight loss outcomes and lean body mass preservation. In one study of 138 patients prescribed GLP-1s with normal dose escalation who used the VCS, patients increased lean body mass by an average of 6.1%, increased muscle mass by an average of 6.4%, and decreased fat mass by an average of 10.2% after four months of using the VCS, indicating that Allurion’s AI-driven behavioral support may help patients maintain muscle, even at normal or high doses of GLP-1 therapy. In another study of 60 patients who were treated with the Allurion Balloon and then semaglutide, patients achieved an average of 21.2% reduction in total body weight and improvements in metabolic parameters over a 10-month period. This combination therapy approach led to outcomes similar to those achieved with bariatric surgery. Two other studies pertaining to the Allurion Program were also presented at ECO. In one study, 43 patients prescribed GLP-1s who used the VCS achieved an average of 17.3% reduction in total body weight at nine months. Improved weight loss outcomes were observed in this study compared to the weight loss observed in US studies where the VCS was not used. Such other studies reported an average of 15.2% total body weight loss for patients prescribed tirzepatide and an average of 7.9% total body weight loss for patients prescribed semaglutide, each at 12 months2. These outcomes suggest that AI-driven interventions can play a crucial role in augmenting traditional treatment methods. In another study, which was a large single-center experience of 2000 patients treated between 2017 and 2024 with the Allurion Program, patients achieved an average weight reduction of 12.4% after four months with an average of 9.8% increase in muscle mass after six months. These results demonstrate a potentially safe, effective, and scalable program for obesity clinics.”